|ADVENTRX Pharmaceuticals Gets Notice About Exelbine|
|By Staff and Wire Reports|
|Wednesday, 06 October 2010 07:50|
"We remain on track to submit a New Drug Application for Exelbine this quarter," stated Brian M. Culley, Chief Executive Officer of ADVENTRX.
The patent claims are directed to formulations of vinorelbine bitartrate and provide protection for the Company's lead product candidate, ANX-530 (vinorelbine injectable emulsion), or Exelbine?. The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that, upon timely payment of applicable fees, a patent will be issued. Once issued, before taking into account patent term extension, the patent will provide coverage for Exelbine until July 2024.
Back in March,the FDA accepted the proposed proprietary name Exelbine for the Company's product candidate ANX-530, which is manufactured at the Company's intended commercial manufacturing site. Exelbine is a novel emulsion formulation of a currently marketed chemotherapy drug. The company believes Exelbine may improve the safety of and have greater commercial potential than the currently marketed reference product.
The stock closed down slightly on Tuesday at $2.02.